|
MedChemExpress
ezetimibe solutions  Ezetimibe Solutions, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/ezetimibe solutions/product/MedChemExpress Average 93 stars, based on 1 article reviews
ezetimibe solutions - by Bioz Stars,
2026-02
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Heliyon
Article Title: Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
doi: 10.1016/j.heliyon.2023.e21343
Figure Lengend Snippet: Effects of Ezetimibe on the viability, proliferation, and cell cycle of TNBC cells. (A) Viability of MDA-MB-231 and 4T1 cells treated with different concentrations of Ezetimibe (0, 1, 5, 10, 15, 20, 40, 60, 80, 100 μmol/L) for 48 h was detected using the CCK-8 assay. (B) Cell cloning experiments were performed to measure the colony formation of MDA-MB-231 cells after 10 days and 4T1 cells after 14 days of treatment with different concentrations of Ezetimibe (0, 20, 40 μmol/L). (C) Flow cytometry analysis was conducted to examine cell cycle distribution of MDA-MB-231 and 4T1 cells treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h. (D) Western blotting was performed to determine the expression levels of Ki67, CDK2, CDK4, and CyclinD1 proteins in MDA-MB-231 and 4T1 cells treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h. Representative results from three independent experiments are shown, and the data are presented as mean ± standard deviation (Mean ± SD): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Here 0 μmol/L Ezetimibe refers to 0.1 % (v/v) DMSO solution.
Article Snippet:
Techniques: CCK-8 Assay, Clone Assay, Flow Cytometry, Western Blot, Expressing, Standard Deviation
Journal: Heliyon
Article Title: Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
doi: 10.1016/j.heliyon.2023.e21343
Figure Lengend Snippet: Effects of Ezetimibe on the transcriptome of TNBC cells and its impact on levels of PDGFRβ mRNA and protein. (A) MDA-MB-231 cells were treated with 20 μM Ezetimibe for 48 h, followed by transcriptome sequencing. Genes with fold change >2 for upregulation and <0.6 for downregulation were selected as differentially expressed genes between the 20 μM Ezetimibe treatment group and the control group. (B) Volcano plot of differential genes in(A). (C) and (D) Gene Ontology was utilized to extract and merge enriched pathways, and the distribution of enriched q-values for each pathway was plotted. (C) Represents the pathway enrichment analysis for the upregulated genes in (A), while (D) represents the pathway enrichment analysis for the downregulated genes in (A). (E) MDA-MB-231 and 4T1 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h, and the mRNA levels of PDGFRβ were measured using qRT-PCR. (F) MDA-MB-231 and 4T1 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h, and the expression of PDGFRβ protein was assessed using Western blot. The representative results shown in the figure are the mean ± standard deviation (Mean ± SD) of three independent experiments: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Here 0 μmol/L Ezetimibe refers to 0.1 % (v/v) DMSO solution.
Article Snippet:
Techniques: Sequencing, Control, Quantitative RT-PCR, Expressing, Western Blot, Standard Deviation
Journal: Heliyon
Article Title: Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
doi: 10.1016/j.heliyon.2023.e21343
Figure Lengend Snippet: The impact of PDGFRβ overexpression on the inhibition of MDA-MB-231 and 4T1 cell proliferation and the ability of Ezetimibe to arrest the cell cycle. (A) (B) qRT-PCR and Western blotting were respectively performed to detect the mRNA and protein levels of PDGFRβ in PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, respectively, as well as in the control group cells. (C) PDGFRβ-overexpressing or vector-transfected MDA-MB-231 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 10 days, while PDGFRβ-overexpressing or vector-transfected 4T1 cells were treated for 14 days. The cell clone formation experiment was conducted to determine the number of cell clones formed. (D) PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, as well as vector-transfected control cells, were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h, and flow cytometry was used to detect the cell cycle distribution. (E) PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, as well as vector-transfected control group cells, were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h. Western blotting was used to examine the expression of Ki67, CDK2, CDK4, and Cyclin D1 proteins. (F) PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, as well as vector-transfected control group cells, were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) for 48 h. Western blotting was performed to analyze the expression of PDGFRβ, t -AKT, and p -AKT473 proteins. The results presented in the figure are representative of three independent experiments and are expressed as the mean ± standard deviation (Mean ± SD): *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001. Here 0 μmol/L Ezetimibe refers to 0.1 % (v/v) DMSO solution.
Article Snippet:
Techniques: Over Expression, Inhibition, Quantitative RT-PCR, Western Blot, Control, Plasmid Preparation, Transfection, Clone Assay, Flow Cytometry, Expressing, Standard Deviation
Journal: Heliyon
Article Title: Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
doi: 10.1016/j.heliyon.2023.e21343
Figure Lengend Snippet: The effects of AKT activation on the inhibition of MDA-MB-231 and 4T1 cell proliferation and cell cycle arrest by Ezetimibe. (A) MDA-MB-231 and 4T1 cells were treated with different concentrations of SC79 (0, 0.5, 1, 5, 10, 15, 20, 40 μmol/L) for 48 h, and cell viability was measured using the CCK-8 assay. (B) MDA-MB-231 and 4T1 cells were treated with SC79 (0, 10 μmol/L) for 48 h, and the levels of t -AKT and p -AKT473 were detected using Western blotting analysis. (C) MDA-MB-231 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) and SC79 (0, 10 μmol/L) for 10 days, and 4T1 cells were treated for 14 days. The cell colony formation assay was used to measure the number of cell colonies formed. (D) MDA-MB-231 and 4T1 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) and SC79 (0, 10 μmol/L) for 48 h, and cell cycle distribution was analyzed using flow cytometry. (E) MDA-MB-231 and 4T1 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) and SC79 (0, 10 μmol/L) for 48 h, and the expression levels of Ki67, CDK2, CDK4, and CyclinD1 proteins were determined by Western blotting analysis. (F) MDA-MB-231 and 4T1 cells were treated with different concentrations of Ezetimibe (0, 20, 40 μmol/L) and SC79 (0, 10 μmol/L) for 48 h, and the levels of PDGFRβ, t -AKT, and p -AKT473 proteins were measured by Western blotting analysis. The results shown in the figure are representative of three independent experiments and are presented as mean ± standard deviation (Mean ± SD): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Here 0 μmol/L Ezetimibe, SC79 or other chemicals refers to 0.1 % (v/v) DMSO solution.
Article Snippet:
Techniques: Activation Assay, Inhibition, CCK-8 Assay, Western Blot, Colony Assay, Flow Cytometry, Expressing, Standard Deviation
Journal: Heliyon
Article Title: Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
doi: 10.1016/j.heliyon.2023.e21343
Figure Lengend Snippet: The impact of MK2206 on the inhibitory effect on the proliferation and cell cycle arrest of PDGFRβ overexpressing TNBC cells by Ezetimibe. (A) MDA-MB-231 and 4T1 cells overexpressing PDGFRβ or transfected with empty vector were treated with different concentrations of MK2206 (0, 0.5, 1, 5, 10, 15, 20, 40 μmol/L) for 48 h, and cell viability was measured using the CCK-8 assay. (B) MDA-MB-231 and 4T1 cells were treated with MK2206 (0, 1 μmol/L) for 48 h, and the expression of t -AKT and p -AKT473 was examined by Western blot. (C) MDA-MB-231 cells overexpressing PDGFRβ or transfected with empty vector were treated with different concentrations of MK2206 (0, 1 μmol/L) and Ezetimibe (0, 20, 40 μmol/L) for 10 days, and 4T1 cells were treated for 14 days. Cell clony formation was assessed by colony formation assay. (D) PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, as well as control cells, were treated with different concentrations of MK2206 (0, 1 μmol/L) and Ezetimibe (0, 20, 40 μmol/L) for 48 h, and cell cycle distribution was analyzed by flow cytometry. (E) PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, as well as control cells, were treated with different concentrations of MK2206 (0, 1 μmol/L) and Ezetimibe (0, 20, 40 μmol/L) for 48 h, and the expression of Ki67, CDK2, CDK4, and CyclinD1 proteins was examined by Western blot. (F) PDGFRβ-overexpressing MDA-MB-231 and 4T1 cells, as well as control cells, were treated with different concentrations of MK2206 (0, 1 μmol/L) and Ezetimibe (0, 20, 40 μmol/L) for 48 h, and the expression of PDGFRβ, t -AKT, and p -AKT473 proteins was examined by Western blot. The results shown in the figures represent the mean ± standard deviation (Mean ± SD) of three independent experiments. Statistical significance is denoted as: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Here 0 μmol/L Ezetimibe, MK2206 or other chemicals refers to 0.1 % (v/v) DMSO solution.
Article Snippet:
Techniques: Transfection, Plasmid Preparation, CCK-8 Assay, Expressing, Western Blot, Colony Assay, Control, Flow Cytometry, Standard Deviation
Journal: Heliyon
Article Title: Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
doi: 10.1016/j.heliyon.2023.e21343
Figure Lengend Snippet: The effects of Ezetimibe on TNBC growth and the PDGFRβ/AKT pathway in vivo. (A) MDA-MB-231 cells overexpressing PDGFRβ or transfected with empty vector were separately used to establish subcutaneous breast tumor models in mice. When the tumors reached a size of 5 mm in length, the mice were randomly divided into 8 groups, with 5 mice in each group. The groups received the following treatments: LVCONTROL (empty vector MDA-MB-231) with vehicle treatment, LVCONTROL + ezetimibe (empty vector MDA-MB-231) treated with ezetimibe alone, LVPDGFRB (PDGFRβ-overexpressing MDA-MB-231) with vehicle treatment, LVPDGFRB + ezetimibe (PDGFRβ-overexpressing MDA-MB-231) treated with ezetimibe alone, LVPDGFRB + MK2206 (PDGFRβ-overexpressing MDA-MB-231) treated with MK2206 alone, LVPDGFRB + ezetimibe + MK2206 (PDGFRβ-overexpressing MDA-MB-231) treated with the combination of ezetimibe and MK2206, LVCONTROL + SC79 (empty vector MDA-MB-231) treated with SC79 alone, and LVCONTROL + ezetimibe + SC79 (empty vector MDA-MB-231) treated with the combination of ezetimibe and SC79. During the treatment process, the body weight (A) and tumor length and width (B) were measured at regular intervals. The tumor volume was calculated using the formula: length × width 2 /2. (C) When the tumor volume reached 2000 mm 3 , the mice were euthanized while under anesthesia, and the tumors were harvested and photographed. (D) Tumors from xenograft mice with breast cancer were harvested when they reached a size of 2000 mm 3 . Immunohistochemical staining was performed on the xenograft tumors from each group to detect the expression levels of Ki67, CDK2, CDK4, and CyclinD1. Representative images were captured under a microscope at a magnification of × 400. (E) Immunohistochemical staining was performed on the xenograft tumors from each group to detect the expression levels of PDGFRβ, AKT, and p -AKT473. Representative images were captured under a microscope at a magnification of × 400. The results presented in the figures are representative of three independent experiments and are expressed as mean ± standard deviation (Mean ± SD): *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Article Snippet:
Techniques: In Vivo, Transfection, Plasmid Preparation, Immunohistochemical staining, Staining, Expressing, Microscopy, Standard Deviation